retatrutide nonalcoholic fatty liver disease trial significantly improved health in patients with non-alcoholic liver Experimental weight-loss drug slashed fat

Achlorhydria clinical presentation: History

Key Takeaways Triple agonist mechanism: Retatrutide is the first medication to activate GIP, GLP-1, and glucagon receptors simultaneously GLP-1 component reduces appetite and slows gastric emptying, the core appetite suppression pathway GIP component improves insulin sensitivity and promotes favorable fat distribution Glucagon component increases energy expenditure through thermogenesis and promotes fat breakdown Weight loss: Phase 2 trials showed up to 24.2% weight loss at 48 weeks, compared to tirzepatide (~22%) and semaglutide (~15%) Investigational status: Not FDA-approved

During stress, AMPK inhibits mTOR, shifting the cell away from growth and toward repair

The market is being reshaped by 6 forces: Market size: $94B today $216B+ by 2035 (8.8% CAGR) Oral GLP-1s just got FDA approval eliminating the needle barrier for millions WHO officially recommends GLP-1s for long-term obesity treatment (Dec 2025) Novo Nordisk slashed Ozempic/Wegovy prices by up to 70% unlocking mass adoption Next-gen tri-agonists (retatrutide) showing 28.7% weight loss in trials Only ~7% diabetes penetration and ~2% obesity penetration the growth runway is massive The ripple effects extend far beyond pharma: Food & beverage: $30$55B annual revenue at risk as GLP-1 users cut calories by 21% Employers: 77% of large companies say managing GLP-1 costs is a top priority Eli Lilly became the first pharma company to surpass $1 trillion market cap ~150 GLP-1 drugs now in development globally 2530 million Americans projected on GLP-1 therapy by 2030 The question isnt whether GLP-1s will reshape global healthcare

If you're already on a GLP-1 for weight loss, you may qualify for the Bridge program